Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

EAST HANOVER, N.J., Sept. 23, 2011 /PRNewswire/ -- A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. Findings from the trial, known as EXIST-2, were presented today at the International TSC Research Conference in Belfast, Northern Ireland(1).

Tuberous sclerosis complex is a genetic disorder that may cause non-cancerous tumors to form in vital organs, including the brain (SEGAs) and kidney (angiomyolipomas)(3). These kidney tumors occur in up to 80% of patients, usually occurring between the ages of 15 and 30 and increasing in prevalence with age(2,3). Angiomyolipomas are the greatest cause of morbidity and mortality in adult TSC patients, as larger tumors may cause severe bleeding, require surgical intervention or result in kidney failure(2,3). Tumor symptoms may include nausea, vomiting, pain and bleeding(3,6,7).

Results of the 118-patient, randomized, placebo-controlled Phase III EXIST-2 (EXamining everolimus In a Study of TSC) trial showed 42% of patients (33 of 79) experienced a response in the everolimus arm versus 0% of patients (0 of 39) on placebo (p<0.0001) based on best overall response rate(1). These results add to the recent positive Phase III data from a separate trial in patients with TSC, which demonstrated reduction in the size of non-cancerous brain tumors (SEGAs) with everolimus(5).

"For the first time, a large placebo-controlled study has focused specifically on angiomyolipomas in TSC patients, an area with clear unmet need," said Dr. John Bissler, lead study author and Clark D. West Endowed Chair of Nephrology at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. "In addition to the tumor reduction seen with everolimus in this trial, s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 25, 2015 ... the addition of the "2015 New ... Challenges, Emerging Technologies, Competitive Landscape" report ... Frontiers in Clinical Chemistry and Immunodiagnostics: Global ... new seven-country strategic analysis of major business ...
(Date:7/2/2015)... 2 de julio de 2015 BGI anunció ... de alto rendimiento en Hong Kong ... of Pathologists (CAP). La instalación de BGI en ... secuenciación de próxima generación que recibe la certificación CAP ... alto estándar en prácticas de laboratorio clínico. Junto con ...
(Date:7/2/2015)... July 2, 2015 ALPINION MEDICAL SYSTEMS Co., ... Series ultrasound system. Developed to enhance user experience and ... E-CUBE 15 EX produces superb image quality. With advanced ... women,s health, general imaging, and shared service applications. ... in the renowned E-CUBE Series, the E-CUBE 15 EX ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI recibe la acreditación del College of American Pathologists (CAP) 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3
... Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... chairman and chief executive officer, will present at CL ... September 14, 2011 at 9:00 a.m. ET. The conference ... in New York City. About Abaxis ...
... 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... President and Chief Executive Officer, will present at the ... NY at The Waldorf Astoria. The presentation is scheduled ...
Cached Medicine Technology:Abaxis, Inc. to Present at CL King's 9th Annual Best Ideas Conference 2011 2AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference 2
(Date:7/2/2015)... ... ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, as ... first poem, and three years later he was publishing an entire book of poetry. He ... world. "I have always believed that the best way to lift yourself up, is in ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have ... Their significant popularity has inspired four new, fun shades including: blue, lime, pink ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... The ZAC ... the 2015 swim season with important lessons on how to stay water safe with ... Who Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety ...
(Date:7/2/2015)... Dallas, TX (PRWEB) , ... ... ... “Negative pressure wound therapy (NPWT) - pipeline review 2015” provides comprehensive information ... stages of development. Complete report on negative pressure wound therapy (NPWT) with ...
(Date:7/2/2015)... ... July 02, 2015 , ... Facial plastic surgery ... precision. There is an art and science that goes into successful facial reconstruction ... the facial features and lives of more than 2,500 satisfied facelift and neck ...
Breaking Medicine News(10 mins):Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3
... Wednesday, May 7, Cedar,Point amusement park/resort will host the ... this special event will benefit the,Firelands Chapter of the ... at Cedar Point,s Challenge Park and will,be a four-person, ... shotgun start at 4:30 p.m. Teams of four can ...
... are highly effective at preventing acute respiratory illness and ... worse, according to research published in the April issue ... , A study of 87 patients with chronic obstructive ... health and death - found that having the annual ...
... CDI Program Utilizing the Expertise of Two Industry ... ... 15 Precyse Solutions, the leader in,driving peak performance within Health ... robust service,offerings and highly qualified team of HIM experts. Noted professionals ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading ... aesthetic treatment systems, today announced that the company,will ... April 29, 2008,at 9:00 a.m. ET., On ... Davin and,Executive Vice President and Chief Financial Officer ...
... Benefits of Healthy, Wholesome Foods, JACKSONVILLE, Fla., April ... including those among children -- are at an all-time ... nutritional,information aimed at helping the youngest members of society ... resources like these,are few and far between., But ...
... they are to undergo screenings , , TUESDAY, April 15 ... women perceive their cancer risk may influence how likely ... cancer, says a University of California, San Francisco study. ... to 80, about breast, cervical and colon cancer. The ...
Cached Medicine News:Health News:Flu vaccines can reduce respiratory problems by up to 3/4 2Health News:Flu vaccines can reduce respiratory problems by up to 3/4 3Health News:Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues 2Health News:Cynosure to Announce First-Quarter 2008 Financial Results on April 29 2Health News:Professor Woodpecker Makes Children's Nutrition Fun and Simple 2Health News:Professor Woodpecker Makes Children's Nutrition Fun and Simple 3Health News:Women's Awareness of Cancer Risk Linked to Race, Ethnicity 2
... SheerVision manufactures its signature line ... are available in a lightweight, yet ... loupes feature extremely high resolution razor-sharp ... are multi-coated lens for anti-glare, anti-fog, ...
... SheerVision is now the first ... loupes directly to the wearer. These ... resolution razor-sharp clarity, an ultra-lightweight design, ... anti-fog, and scratch resistance. With SheerVision's ...
Easy pull-on garment's feature Rainey's exclusive Non-Slip Dome™design and adjustable Velcro© closure at neck for optimal comfort and support. Choose covered or non covered ear design....
Facial Wrap...
Medicine Products: